intarcia therapeutics
-
Twice Rejected Diabetes Drug/Device Product Gets New Chance at Startup i2o
Intarcia Therapeutics’ GLP-1 agonist product candidate for type 2 diabetes now belongs to i2o Therapeutics, which will make the treatment’s case for approval at an upcoming FDA advisory committee meeting. The startup’s $46 million Series A financing is one of several recently announced funding rounds.
-
NEA’s Ed Mathers talks biopharma investment trends and why it’s worth sticking around
It’s safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharma industry — 15 of which have been spent on the investor side. So what’s his take on today’s high potential therapeutic areas?
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.